IL160231A0 - Adenosine a3 receptor agonists - Google Patents

Adenosine a3 receptor agonists

Info

Publication number
IL160231A0
IL160231A0 IL16023102A IL16023102A IL160231A0 IL 160231 A0 IL160231 A0 IL 160231A0 IL 16023102 A IL16023102 A IL 16023102A IL 16023102 A IL16023102 A IL 16023102A IL 160231 A0 IL160231 A0 IL 160231A0
Authority
IL
Israel
Prior art keywords
receptor agonists
adenosine
neutropennia
leukopenia
useful
Prior art date
Application number
IL16023102A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL160231A0 publication Critical patent/IL160231A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL16023102A 2001-08-08 2002-08-06 Adenosine a3 receptor agonists IL160231A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106901P 2001-08-08 2001-08-08
PCT/US2002/024696 WO2003014137A1 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists

Publications (1)

Publication Number Publication Date
IL160231A0 true IL160231A0 (en) 2004-07-25

Family

ID=23205248

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16023102A IL160231A0 (en) 2001-08-08 2002-08-06 Adenosine a3 receptor agonists
IL160231A IL160231A (en) 2001-08-08 2004-02-05 Adenosine a3 receptor agonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160231A IL160231A (en) 2001-08-08 2004-02-05 Adenosine a3 receptor agonists

Country Status (20)

Country Link
US (1) US20030078232A1 (pl)
EP (1) EP1414837B1 (pl)
JP (1) JP4357960B2 (pl)
KR (1) KR100923888B1 (pl)
CN (1) CN1244589C (pl)
AT (1) ATE307136T1 (pl)
AU (1) AU2002327426C1 (pl)
CA (1) CA2456744A1 (pl)
DE (1) DE60206775T2 (pl)
DK (1) DK1414837T3 (pl)
ES (1) ES2247371T3 (pl)
HU (1) HUP0401437A3 (pl)
IL (2) IL160231A0 (pl)
MX (1) MXPA04001185A (pl)
NO (1) NO327997B1 (pl)
NZ (1) NZ530976A (pl)
PL (1) PL368205A1 (pl)
RU (1) RU2298557C2 (pl)
WO (1) WO2003014137A1 (pl)
ZA (1) ZA200401000B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AU2003268526A1 (en) * 2002-09-09 2004-03-29 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
AU2004261459B2 (en) 2003-07-22 2008-06-26 Astex Therapeutics Limited 3, 4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
EP1819349A2 (en) * 2004-11-22 2007-08-22 King Pharmaceuticals Research and Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
KR101346886B1 (ko) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US7514417B2 (en) 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7488720B2 (en) 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
AU2008231695B2 (en) 2007-03-28 2013-03-28 Novartis Ag Purinyl derivatives and their use as potassium channel modulators
US20120004246A1 (en) * 2007-03-28 2012-01-05 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
US20090099212A1 (en) * 2007-10-16 2009-04-16 Jeff Zablocki A3 adenosine receptor antagonists
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
RU2451010C1 (ru) * 2011-01-11 2012-05-20 Закрытое Акционерное Общество "Ива Фарм" Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия
CN104411703A (zh) 2012-06-26 2015-03-11 萨尼奥纳有限责任公司 苯基三唑衍生物及其调节gabaa受体复合体的用途
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof
SG11201909932YA (en) * 2017-05-19 2019-11-28 Alltech Inc Pharmaceutical agents, compositions, and methods relating thereto
EP3937964B1 (en) 2019-03-12 2026-03-11 Arcus Biosciences, Inc. Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP3988100A4 (en) * 2019-06-21 2023-07-26 Academy of Military Medical Sciences ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF AND USE
EP4273153A4 (en) * 2020-12-29 2024-05-08 Zhejiang Vimgreen Pharmaceuticals, Ltd ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists

Also Published As

Publication number Publication date
JP4357960B2 (ja) 2009-11-04
CN1538972A (zh) 2004-10-20
EP1414837B1 (en) 2005-10-19
JP2005501842A (ja) 2005-01-20
AU2002327426B2 (en) 2007-06-14
HUP0401437A3 (en) 2007-05-29
IL160231A (en) 2010-11-30
ES2247371T3 (es) 2006-03-01
NO20040969L (no) 2004-04-19
NZ530976A (en) 2005-07-29
DE60206775T2 (de) 2006-07-20
CN1244589C (zh) 2006-03-08
DE60206775D1 (de) 2006-03-02
KR20040023733A (ko) 2004-03-18
RU2298557C2 (ru) 2007-05-10
DK1414837T3 (da) 2005-11-07
HUP0401437A2 (hu) 2004-11-29
ZA200401000B (en) 2004-10-18
AU2002327426A2 (en) 2003-02-24
MXPA04001185A (es) 2005-06-17
NO327997B1 (no) 2009-11-09
WO2003014137A1 (en) 2003-02-20
RU2004106635A (ru) 2005-07-27
AU2002327426C1 (en) 2008-03-06
CA2456744A1 (en) 2003-02-20
EP1414837A1 (en) 2004-05-06
PL368205A1 (pl) 2005-03-21
US20030078232A1 (en) 2003-04-24
ATE307136T1 (de) 2005-11-15
KR100923888B1 (ko) 2009-10-28

Similar Documents

Publication Publication Date Title
IL160231A0 (en) Adenosine a3 receptor agonists
MY133996A (en) Compounds for the treatment of ischemia
DE60206512D1 (de) Rapanycin29-enole
ATE293618T1 (de) 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel
NO20020684L (no) 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
DZ3168A1 (fr) Dérivés de purine.
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
NO20012058D0 (no) 2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
PT1444215E (pt) Derivados de 1,2,4-triadiazolio como moduladores do receptor de melanocortina
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
MA26846A1 (fr) Derives de 2,4-diaminopyrimidine utiles comme agents immunosuppresseurs.
ZA200201788B (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain.
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
MXPA03002323A (es) Metodos de diagnostico de cancer colorectal, composiciones y metodos para seleccionar moduladores de cancer colorectal.
NO2010004I1 (no) 0,02 mg etinylostradiol (som betadexclathrat) og 3mg drospirenon
AU2002223084A1 (en) Nitrogen substituted 1,2,4-triazolo(3,4-a)phthalazine derivatives for enhancing cognition
HK1043058A1 (zh) 异环磷酰胺芥子类似物及其用途
WO2004022573A3 (en) Adenosine a3 receptor agonists
ES2166045T3 (es) Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.
WO2003039484A3 (en) Novel compositions and methods for cancer
WO1999043285A3 (en) Sulphonamide derivatives